Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

REGN 9933

Next Previous
X
Search
Drug Profile

REGN 9933

Alternative Names: REGN-9933

Latest Information Update: 18 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Regeneron Pharmaceuticals
  • Class Antithrombotics; Monoclonal antibodies
  • Mechanism of Action Factor XI inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Venous thromboembolism
  • Phase I Thrombosis

Most Recent Events

  • 12 Jun 2024 Regeneron Pharmaceuticals plans a phase I trial in healthy adults volunteers (Combination therapy) in October 2024 (IV) (NCT06444178)
  • 27 May 2024 Regeneron Pharmaceuticals completes a phase II trial in Venous thromboembolism in Belgium, Bulgaria, Canada, Hungary, Latvia, Lithuania, Poland (IV) (EudraCT2022-501470-18-00) (NCT05618808)
  • 07 Mar 2024 Regeneron Pharmaceuticals plans a phase-II trial for Venous thromboembolism (Prevention) in August 2024 (IV) (NCT06299111)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top